Ibnsina Pharma (CAI:ISPH) Research & Development: E£0 Mil (TTM As of Mar. 2026)


CAI:ISPH Ibnsina Pharma CAI:ISPH
85 GF Score
Price E£11.67
GF Value E£10.46
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Ibnsina Pharma Research & Development?

Ibnsina Pharma CAI:ISPH +1.92% 85 Research & Development is E£0 Mil as of Mar. 2026. GuruFocus rates CAI:ISPH with a GF Score™ of 85/100 and a GF Value™ of E£10.46 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Ibnsina Pharma's Research & Development for the three months ended in Mar. 2026 was E£0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was E£0 Mil.

Ibnsina Pharma  (CAI:ISPH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Ibnsina Pharma Research & Development Related Terms

Ibnsina Pharma Research & Development Historical Data

* Premium members only.

The historical data trend for Ibnsina Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ibnsina Pharma Research & Development Chart

Ibnsina Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ibnsina Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CAI:ISPH
85GF Score
Ibnsina Pharma CAI:ISPH
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ibnsina Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of E£0 Mil mean?
Ibnsina Pharma (CAI:ISPH) has a Research & Development of E£0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Ibnsina Pharma and its competitors.
Is Ibnsina Pharma's Research & Development too high?
Ibnsina Pharma's current Research & Development is E£0 Mil. Overall, Ibnsina Pharma has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ibnsina Pharma's Research & Development compare to MCK and CAH?
Ibnsina Pharma's Research & Development of E£0 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Distribution company?
A good Research & Development depends on the Medical Distribution industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Ibnsina Pharma and its competitors. Ibnsina Pharma's current Research & Development is E£0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ibnsina Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ibnsina Pharma (CAI:ISPH) is currently considered Modestly Overvalued. The stock's GF Value™ is E£10.46, compared to a current price of E£11.67 — trading 11.6% above its estimated fair value. The current Research & Development is E£0 Mil. Ibnsina Pharma's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Ibnsina Pharma (CAI:ISPH), the current Research & Development is E£0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?

Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued. The current stock price of E£11.67 is trading 11.6% above its estimated GF Value™ of E£10.46. GuruFocus considers Ibnsina Pharma to be Modestly Overvalued.

Key valuation signals for CAI:ISPH:

  • Research & Development: E£0 Mil
  • GF Value™: E£10.46 vs. price of E£11.67 (11.6% above fair value)
  • GF Score™: 85/100 with 7 warning signs

No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ibnsina Pharma Business Description

Address Industrial zone 1, PO box 91, Obour, EGY
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
85GF Score

Get the complete analysis for CAI:ISPH

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£11.67
Price
E£10.46
GF Value